As of November 22, 2026, Polymarket prices “New COVID variant of concern before 2027?” at 5% YES with $248K traded. No tracked wallet holds a position on this market, so there is no verdict.
Prediction markets put the probability at 5%: New COVID variant of concern before 2027. Currently, markets see this as unlikely (5% YES). The identification of variants and mutations occurs through whole genome sequencing (WGS) of select samples.
Ontario's genomic surveillance program continues to sequence SARS-CoV-2 samples to identify mutations with clinical or public health significance, classifying them as variants of concern (VOC) when evidence warrants. The province's November 2 update listed previously designated VOCs including Alpha, Beta, Gamma, Delta and Omicron, noting that some have been de-escalated as their prevalence diminished. The framework matters for the current market question because a formal VOC designation requires evidence of increased transmissibility, severity or immune escape — criteria that separate routine variant tracking from a formal escalation. [Public Health Ontario, Nov 02]
The variant drawing the most attention in November 2026 is PJ.2.1, first detected in Ontario, Canada on May 2, 2026 and since spread to parts of the United States, Europe and Asia. Wastewater surveillance data showed PJ.2.1 was the fastest-growing Covid-19 variant in the US, though findings published in the Journal of Infection suggest it does not significantly evade antibodies produced by existing vaccines. The World Health Organization has noted symptoms closely resemble those of the common cold and flu, with no conclusive evidence of increased severe illness risk. No new COVID variant of concern has been designated in this reporting period. [Times of India, Nov 12]
Public health infrastructure remains active heading into the 2026–2027 respiratory season. The FDA recently approved a new mRNA-based flu shot for people over 50, expected to be available in the US for the 2026–2027 season, while the American Academy of Pediatrics and IDSA issued recommendations for the 2026–2027 Formula COVID-19 vaccines, including routine doses for immunocompromised people and a second booster 2 to 6 months after the first based on shared decision-making. Continued genomic monitoring and wastewater surveillance are the primary mechanisms through which any future new COVID variant of concern would be detected and classified before 2027. [NewYork-Presbyterian, Nov 06]
None of the 166 tracked wallets holds a position here, so the Radar makes no call — price, volume and news above are live. When a tracked wallet takes a position, this page gets a verdict.
See the markets with a verdict →